Cayman BAY 57-1293

BAY-57-1293 is an orally bioavailable helicase-primase inhibitor. It inhibits the ATPase activity of herpes simplex virus (HSV) helicase-primase (IC₅₀ = 30 nM). It inhibits HSV replication in Vero cells (IC₅₀ = 20 nM for both HSV-1 and HSV-2) and is also active against porcine and bovine HSV strains (IC₅₀s = 5 and 0.12 μM, respectively). In vivo, oral administration of BAY-57-1293 is effective against HSV-1 and HSV-2 in a lethal challenge model (ED₅₀ = 0.5 mg/kg in mice and rats) and in a zosteriform spread model, at a dose of 15 mg/kg, in mice and Lewis rats.^, It is also effective in a guinea pig model of genital herpes and a mouse model of ocular herpes. BAY-57-1293 reduces levels of amyloid-beta (Aβ) and phosphorylated Tau in HSV-1 infected Vero cells.

WARNING This product is not for human or veterinary use.